Literature DB >> 15916052

Prevalence of strongyloides in Northern Thailand and treatment with ivermectin vs albendazole.

Ponganant Nontasut1, Chatree Muennoo, Surapol Sa-nguankiat, Sutep Fongsri, Adulsak Vichit.   

Abstract

The stools of 697 cases were examined by agar plate technique at Tambon Makam Luang, Sun Pa Tong district, Chiang Mai; there were Strongyloides stercoralis 15.9%,Opisthorchis viverrini 5.1%, intestinal fluke 0.1%. Treatment with ivermectin 78 cases and albendazole 33 cases of strongyloidiasis gave cure rates at 98.7% and 78.7%, respectively. Alkaline phosphatase in some patients were increased at mild level after treatment. Side effects in ivermectin group were anorexia, nausia, diarrhea, diffuse itching and drowsiness; and in albendazole group were nausia and diarrhea. The efficacy of single dose and mild side effects suggest ivermectin as drug of choice for strongyloidiasis treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15916052

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN: 0125-1562            Impact factor:   0.267


  34 in total

1.  Comparative evaluation of Strongyloides ratti and S. stercoralis larval antigen for diagnosis of strongyloidiasis in an endemic area of opisthorchiasis.

Authors:  Chatanun Eamudomkarn; Paiboon Sithithaworn; Jiraporn Sithithaworn; Sasithorn Kaewkes; Banchob Sripa; Makoto Itoh
Journal:  Parasitol Res       Date:  2015-04-17       Impact factor: 2.289

Review 2.  Tropical malabsorption.

Authors:  B S Ramakrishna; S Venkataraman; A Mukhopadhya
Journal:  Postgrad Med J       Date:  2006-12       Impact factor: 2.401

3.  [Transient pruritus in an Ethiopean adoptee in Austria].

Authors:  Rosemarie Moser; Herbert Auer; Christina Prenner-Glas; Georg Klein
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

4.  Comparison between the effect of Lawsonia inermis and flubendazole on Strongyloides species using scanning electron microscopy.

Authors:  Khadiga Ahmed Ismail; Ayman Nabil Ibrahim; Mona Abdel-Fattah Ahmed; Mona Hafez Hetta
Journal:  J Parasit Dis       Date:  2014-08-24

5.  Rapid detection of Opisthorchis viverrini and Strongyloides stercoralis in human fecal samples using a duplex real-time PCR and melting curve analysis.

Authors:  Penchom Janwan; Pewpan M Intapan; Tongjit Thanchomnang; Viraphong Lulitanond; Witthaya Anamnart; Wanchai Maleewong
Journal:  Parasitol Res       Date:  2011-05-03       Impact factor: 2.289

Review 6.  Evidence-Based Guidelines for Screening and Management of Strongyloidiasis in Non-Endemic Countries.

Authors:  Ana Requena-Méndez; Dora Buonfrate; Joan Gomez-Junyent; Lorenzo Zammarchi; Zeno Bisoffi; José Muñoz
Journal:  Am J Trop Med Hyg       Date:  2017-07-27       Impact factor: 2.345

7.  Imported strongyloidiasis: epidemiology, presentations, and treatment.

Authors:  Dora Buonfrate; Andrea Angheben; Federico Gobbi; Jose Muñoz; Ana Requena-Mendez; Eduardo Gotuzzo; Maria Alejandra Mena; Zeno Bisoffi
Journal:  Curr Infect Dis Rep       Date:  2012-06       Impact factor: 3.725

8.  Comparative Diagnosis of Strongyloidiasis in Immunocompromised Patients.

Authors:  Viravarn Luvira; Kitti Trakulhun; Mathirut Mungthin; Tawee Naaglor; Nirattar Chantawat; Wallop Pakdee; Danabhand Phiboonbanakit; Paron Dekumyoy
Journal:  Am J Trop Med Hyg       Date:  2016-06-13       Impact factor: 2.345

9.  An Epidemiological Survey of Opisthorchis viverrini Infection in a Lightly Infected Community, Eastern Thailand.

Authors:  Jitrada Boondit; Picha Suwannahitatorn; Suradej Siripattanapipong; Saovanee Leelayoova; Mathirut Mungthin; Peerapan Tan-Ariya; Phunlerd Piyaraj; Tawee Naaglor; Toon Ruang-Areerate
Journal:  Am J Trop Med Hyg       Date:  2020-04       Impact factor: 2.345

10.  Serological and molecular detection of Strongyloides stercoralis infection among an Orang Asli community in Malaysia.

Authors:  Arine Fadzlun Ahmad; Faizah Hadip; Romano Ngui; Yvonne A L Lim; Rohela Mahmud
Journal:  Parasitol Res       Date:  2013-05-11       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.